Evidence map›Paper›PMID 33891804›Full record

ArticleBiotechnology progress2021

Genetic rearrangement during site specific integration event facilitates cell line development of a bispecific molecule.

Barbara Tevelev, Himakshi Patel, Kathleen Shields, Wei Wei, Cecilia Cooley, Sam Zhang, Gabrielle Bitzas, Weili Duan, Lam Khetemenee, Ryan Jackobek and 11 more

Open access · hybridAbstract read
In one paragraph

Article in Biotechnology progress, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 1 institution in 1 country.

Barbara TevelevCell Line Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA.ORCID 0000-0002-1162-7541
Himakshi PatelAnalytical Research and Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA.
Kathleen ShieldsAnalytical Research and Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA.
Wei WeiCell Line Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA.
Cecilia CooleyCell Line Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA.
Sam ZhangCell Line Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA.
Gabrielle BitzasBioMedicine Design, Pfizer Inc., Andover, Massachusetts, USA.
Weili DuanBioMedicine Design, Pfizer Inc., Andover, Massachusetts, USA.
Lam KhetemeneeBioMedicine Design, Pfizer Inc., Andover, Massachusetts, USA.
Ryan JackobekBioMedicine Design, Pfizer Inc., Andover, Massachusetts, USA.
Aaron D'AntonaBioMedicine Design, Pfizer Inc., Andover, Massachusetts, USA.
Annette SieversBioMedicine Design, Pfizer Inc., Andover, Massachusetts, USA.
Amy KingBioMedicine Design, Pfizer Inc., Andover, Massachusetts, USA.
Amy TamBioMedicine Design, Pfizer Inc., Andover, Massachusetts, USA.
Yan ZhangBioMedicine Design, Pfizer Inc., Andover, Massachusetts, USA.
Eric SousaBioMedicine Design, Pfizer Inc., Andover, Massachusetts, USA.
Justin CohenBioMedicine Design, Pfizer Inc., Andover, Massachusetts, USA.
Lila WroblewskaBioMedicine Design, Pfizer Inc., Andover, Massachusetts, USA.
Jeffrey MarshallAnalytical Research and Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA.
Martha JacksonAnalytical Research and Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA.
John J ScarcelliCell Line Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA.ORCID 0000-0002-3314-7602
Pfizer (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Site specific integration (SSI) expression systems offer robust means of generating highly productive and stable cell lines for traditional monoclonal antibodies. As complex modalities such as antibody-like molecules comprised of greater than two peptides become more prevalent, greater emphasis needs to be placed on the ability to produce appreciable quantities of the correct product of interest (POI). The ability to screen several transcript stoichiometries could play a large role in ensuring high amounts of the correct POI. Here we illustrate implementation of an SSI expression system with a single site of integration for development and production of a multi-chain, bi-specific molecule. A SSI vector with a single copy of all of the genes of interest was initially selected for stable Chinese hamster ovary transfection. While the resulting transfection pools generated low levels of the desired heterodimer, utilizing an intensive clone screen strategy, we were able to identify clones having significantly higher levels of POI. In-depth genotypic characterization of clones having the desirable phenotype revealed that a duplication of the light chain within the landing pad was responsible for producing the intended molecule. Retrospective transfection pool analysis using a vector configuration mimicking the transgene configuration found in the clones, as well as other vector configurations, yielded more favorable results with respect to % POI. Overall, the study demonstrated that despite the theoretical static nature of the SSI expression system, enough heterogeneity existed to yield clones having significantly different transgene phenotypes/genotypes and support production of a complex multi-chain molecule.

Indexed as

CricetulusAnimalsCHO CellsCricetinaeRecombinant ProteinsRetrospective StudiesTransfectionTransgenesRecombinant Proteinsbioprocess developmentCHO cellsgene expression systemmulti-specific moleculesite-specific integration

Identifiers

PMID33891804
PMCPMC8459265
OpenAlexW3155173716

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.